{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:58:00Z","timestamp":1781643480545,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T00:00:00Z","timestamp":1774137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300213"],"award-info":[{"award-number":["82300213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A significant proportion of patients with recurrent and refractory diffuse large B-cell lymphoma (DLBCL) exhibit high levels of BCL-2 expression. However, some of these patients are resistant to BCL-2 inhibitors, and the underlying mechanisms remain unclear. In venetoclax-resistant DLBCL cell line, a Cell Counting Kit-8 (CCK8) assay was used to determine the half-maximal inhibitory concentration (IC\n                    <jats:sub>50<\/jats:sub>\n                    ) value. Flow cytometric was performed to determine mitochondrial membrane potential (MMP), reactive oxygen species (ROS), and cell apoptosis rates, respectively. The construction of NSUN4 knockdown\/overexpression cell line using CRISPR-Cas9 technology. KEGG pathway enrichment analysis indicated that NSUN4 modulates venetoclax resistance. Furthermore, we used Western blotting to explore the mechanism underlying venetoclax-resistant. Finally, the antileukemic activity was further evaluated in an in vivo xenograft model. We identified that NSUN4, an m5C methyltransferase, is highly expressed not only in the venetoclax-resistant cell line but also in the lymph nodes of recurrent and refractory DLBCL patients primarily by inhibiting the p53 signaling pathway, although the precise mechanism warrants further investigation, and is correlated with poor prognosis. Moreover, we discovered that Apatinib could reduce NSUN4 expression and effectively reverse venetoclax resistance. These findings suggest that NSUN4 is a critical target for overcoming venetoclax resistance in DLBCL patients. Our study reveals the role of NSUN4 and the p53 signaling pathway in venetoclax resistance at the molecular, cellular, and animal levels. Understanding how m5C methylation mediates venetoclax resistance and regulates the p53 pathway will provide a theoretical foundation for overcoming venetoclax resistance in patients with recurrent and refractory DLBCL.\n                  <\/jats:p>","DOI":"10.1007\/s10238-026-02117-3","type":"journal-article","created":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T02:55:43Z","timestamp":1774148143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects and molecular mechanism of inhibiting p53 signaling pathway by NSUN4 on the resistance to BCL-2 inhibitor for diffuse large B-cell lymphoma"],"prefix":"10.1007","volume":"26","author":[{"given":"Yuanfei","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heli","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianle","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanzhuo","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,22]]},"reference":[{"issue":"9","key":"2117_CR1","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1158\/2159-8290.CD-23-0802","volume":"14","author":"SR Corcoran","year":"2024","unstructured":"Corcoran SR, et al. Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma. Cancer Discov. 2024;14(9):1653\u201374.","journal-title":"Cancer Discov"},{"key":"2117_CR2","doi-asserted-by":"crossref","unstructured":"Tavakkoli M, Barta SK. 2024 Update: Advances in the risk stratification and management of large B-cell lymphoma. Am J Hematol, 2023. 98(11): pp. 1791\u20131805.","DOI":"10.1002\/ajh.27075"},{"issue":"5","key":"2117_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679\u201390.","journal-title":"Nat Med"},{"issue":"20","key":"2117_CR4","first-page":"2493","volume":"141","author":"W Alduaij","year":"2023","unstructured":"Alduaij W, et al. Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population. Blood. 2023;141(20):2493\u2013507.","journal-title":"Blood"},{"key":"2117_CR5","doi-asserted-by":"crossref","unstructured":"Eken JA et al. Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL. J Exp Med, 2024. 221(5).","DOI":"10.1084\/jem.20230941"},{"issue":"9","key":"2117_CR6","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384(9):842\u201358.","journal-title":"N Engl J Med"},{"key":"2117_CR7","unstructured":"Casta\u00f1o-D\u00edez S et al. AML typical mutations (CEBPA, FLT3, and NPM1) identify a high-risk CMML independent of CPSS-Mol classification. Blood Adv, 2024."},{"issue":"1","key":"2117_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2023022481","volume":"143","author":"F Thol","year":"2024","unstructured":"Thol F, D\u00f6hner H, Ganser A. How I treat refractory and relapsed acute myeloid leukemia. Blood. 2024;143(1):11\u201320.","journal-title":"Blood"},{"issue":"9","key":"2117_CR9","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1002\/ajh.26989","volume":"98","author":"B Falini","year":"2023","unstructured":"Falini B. NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions. Am J Hematol. 2023;98(9):1452\u201364.","journal-title":"Am J Hematol"},{"issue":"10","key":"2117_CR10","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1158\/2159-8290.CD-23-1145","volume":"14","author":"AI Sheth","year":"2024","unstructured":"Sheth AI, et al. Targeting Acute Myeloid Leukemia Stem Cells through Perturbation of Mitochondrial Calcium. Cancer Discov. 2024;14(10):1922\u201339.","journal-title":"Cancer Discov"},{"issue":"7","key":"2117_CR11","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1158\/2159-8290.CD-22-0601","volume":"13","author":"C Glytsou","year":"2023","unstructured":"Glytsou C, et al. Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer Discov. 2023;13(7):1656\u201377.","journal-title":"Cancer Discov"},{"issue":"21","key":"2117_CR12","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.1158\/1078-0432.CCR-23-1429","volume":"29","author":"J Senapati","year":"2023","unstructured":"Senapati J, et al. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed\/Refractory Myeloid Malignancies. Clin Cancer Res. 2023;29(21):4352\u201360.","journal-title":"Clin Cancer Res"},{"issue":"7920","key":"2117_CR13","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/s41586-022-04906-8","volume":"607","author":"E Bal","year":"2022","unstructured":"Bal E, et al. Super-enhancer hypermutation alters oncogene expression in B cell lymphoma. Nature. 2022;607(7920):808\u201315.","journal-title":"Nature"},{"key":"2117_CR14","doi-asserted-by":"crossref","unstructured":"Luo MX et al. Venetoclax Dose Escalation Rapidly Activates a BAFF\/BCL-2 Survival Axis in Chronic Lymphocytic Leukemia. Blood, 2024.","DOI":"10.1182\/blood.2024024341"},{"issue":"13","key":"2117_CR15","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1158\/1078-0432.CCR-22-3321","volume":"29","author":"S Ailawadhi","year":"2023","unstructured":"Ailawadhi S, et al. Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial. Clin Cancer Res. 2023;29(13):2385\u201393.","journal-title":"Clin Cancer Res"},{"key":"2117_CR16","doi-asserted-by":"crossref","unstructured":"Brown FC, et al. Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia. Blood Adv; 2024.","DOI":"10.1182\/bloodadvances.2024014446"},{"issue":"24","key":"2117_CR17","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1182\/blood.2021014241","volume":"140","author":"M Janssen","year":"2022","unstructured":"Janssen M, et al. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1. Blood. 2022;140(24):2594\u2013610.","journal-title":"Blood"},{"issue":"3","key":"2117_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s12032-024-02302-y","volume":"41","author":"IM Bouligny","year":"2024","unstructured":"Bouligny IM, et al. Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia. Med Oncol. 2024;41(3):80.","journal-title":"Med Oncol"},{"key":"2117_CR19","doi-asserted-by":"crossref","unstructured":"Portelinha A et al. SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma. J Exp Med, 2024. 221(10).","DOI":"10.1084\/jem.20231143"},{"issue":"17","key":"2117_CR20","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-21-0464","volume":"27","author":"T Liu","year":"2021","unstructured":"Liu T, et al. Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX-Dependent Manner. Clin Cancer Res. 2021;27(17):4910\u201322.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2117_CR21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1182\/blood-2018-08-872465","volume":"133","author":"K Bojarczuk","year":"2019","unstructured":"Bojarczuk K, et al. Targeted inhibition of PI3K\u03b1\/\u03b4 is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Blood. 2019;133(1):70\u201380.","journal-title":"Blood"},{"issue":"9","key":"2117_CR22","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.cell.2022.03.030","volume":"185","author":"R Pan","year":"2022","unstructured":"Pan R, et al. Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. Cell. 2022;185(9):1521\u2013e153818.","journal-title":"Cell"},{"issue":"4","key":"2117_CR23","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.gendis.2022.07.012","volume":"10","author":"Y Shi","year":"2023","unstructured":"Shi Y, Xu Y, Xie W. Inhibition of VEGFR2 overcomes venetoclax-resistance in diffuse large B-cell lymphoma cells. Genes Dis. 2023;10(4):1147\u20139.","journal-title":"Genes Dis"},{"issue":"20","key":"2117_CR24","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1002\/1878-0261.13309","volume":"16","author":"Y Shi","year":"2022","unstructured":"Shi Y, et al. Apatinib enhances chemosensitivity of ABT-199 in diffuse large B-cell lymphoma. Mol Oncol. 2022;16(20):3735\u201353.","journal-title":"Mol Oncol"},{"issue":"2","key":"2117_CR25","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1001\/jamaoncol.2021.6268","volume":"8","author":"Y Lin","year":"2022","unstructured":"Lin Y, et al. Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial. JAMA Oncol. 2022;8(2):242\u201350.","journal-title":"JAMA Oncol"},{"key":"2117_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ejphar.2018.11.012","volume":"843","author":"Y Wang","year":"2019","unstructured":"Wang Y, et al. Apatinib exerts anti-tumor activity to non-Hodgkin lymphoma by inhibition of the Ras pathway. Eur J Pharmacol. 2019;843:145\u201353.","journal-title":"Eur J Pharmacol"},{"issue":"23","key":"2117_CR27","doi-asserted-by":"publisher","first-page":"23374","DOI":"10.1021\/acsnano.3c04112","volume":"17","author":"MR Schnorenberg","year":"2023","unstructured":"Schnorenberg MR, et al. Targeted Polymersome Delivery of a Stapled Peptide for Drugging the Tumor Protein p53:BCL-2-Family Axis in Diffuse Large B-Cell Lymphoma. ACS Nano. 2023;17(23):23374\u201390.","journal-title":"ACS Nano"},{"issue":"15","key":"2117_CR28","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.molcel.2024.06.023","volume":"84","author":"S Kim","year":"2024","unstructured":"Kim S, et al. RNA 5-methylcytosine marks mitochondrial double-stranded RNAs for degradation and cytosolic release. Mol Cell. 2024;84(15):2935\u201348. .e7.","journal-title":"Mol Cell"},{"issue":"1","key":"2117_CR29","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1038\/s41467-021-23702-y","volume":"12","author":"HS Hillen","year":"2021","unstructured":"Hillen HS, et al. Structural basis of GTPase-mediated mitochondrial ribosome biogenesis and recycling. Nat Commun. 2021;12(1):3672.","journal-title":"Nat Commun"},{"key":"2117_CR30","doi-asserted-by":"crossref","unstructured":"Chandrasekaran V et al. Visualizing formation of the active site in the mitochondrial ribosome. Elife, 2021. 10.","DOI":"10.7554\/eLife.68806"},{"issue":"12","key":"2117_CR31","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.","journal-title":"Genome Biol"},{"issue":"1","key":"2117_CR32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.prosdent.2022.03.001","volume":"131","author":"N Inoue","year":"2024","unstructured":"Inoue N, et al. A comparison of virtually mounted dental casts from traditional facebow records, average values, and 3D facial scans. J Prosthet Dent. 2024;131(1):136\u201343.","journal-title":"J Prosthet Dent"},{"issue":"11","key":"2117_CR33","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498\u2013504.","journal-title":"Genome Res"},{"issue":"8","key":"2117_CR34","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, et al. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol. 2017;35(8):826\u201333.","journal-title":"J Clin Oncol"},{"issue":"17","key":"2117_CR35","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","volume":"27","author":"MS Davids","year":"2021","unstructured":"Davids MS, et al. Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. Clin Cancer Res. 2021;27(17):4690\u20135.","journal-title":"Clin Cancer Res"},{"key":"2117_CR36","doi-asserted-by":"publisher","first-page":"101195","DOI":"10.1016\/j.blre.2024.101195","volume":"65","author":"DJ Fowler-Shorten","year":"2024","unstructured":"Fowler-Shorten DJ, et al. BCL-2 inhibition in haematological malignancies: Clinical application and complications. Blood Rev. 2024;65:101195.","journal-title":"Blood Rev"},{"issue":"6","key":"2117_CR37","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/ajh.25796","volume":"95","author":"S Zhao","year":"2020","unstructured":"Zhao S, et al. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol. 2020;95(6):623\u20139.","journal-title":"Am J Hematol"},{"issue":"22","key":"2117_CR38","doi-asserted-by":"publisher","first-page":"7119","DOI":"10.1158\/1078-0432.CCR-17-1144","volume":"23","author":"CM Adams","year":"2017","unstructured":"Adams CM, et al. Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW. Clin Cancer Res. 2017;23(22):7119\u201329.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2117_CR39","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1158\/2159-8290.CD-22-0998","volume":"13","author":"MM Hoppe","year":"2023","unstructured":"Hoppe MM, et al. Patterns of Oncogene Coexpression at Single-Cell Resolution Influence Survival in Lymphoma. Cancer Discov. 2023;13(5):1144\u201363.","journal-title":"Cancer Discov"},{"issue":"10","key":"2117_CR40","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1182\/bloodadvances.2022009389","volume":"7","author":"PWM Johnson","year":"2023","unstructured":"Johnson PWM, et al. Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial. Blood Adv. 2023;7(10):2008\u201317.","journal-title":"Blood Adv"},{"issue":"16","key":"2117_CR41","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1158\/1078-0432.CCR-22-3887","volume":"29","author":"JA Woyach","year":"2023","unstructured":"Woyach JA, et al. B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy. Clin Cancer Res. 2023;29(16):3065\u201373.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2117_CR42","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","volume":"9","author":"P Blombery","year":"2019","unstructured":"Blombery P, et al. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Cancer Discov. 2019;9(3):342\u201353.","journal-title":"Cancer Discov"},{"issue":"1","key":"2117_CR43","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41467-018-03170-7","volume":"9","author":"CD Herling","year":"2018","unstructured":"Herling CD, et al. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat Commun. 2018;9(1):727.","journal-title":"Nat Commun"},{"issue":"4","key":"2117_CR44","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","volume":"36","author":"R Gui\u00e8ze","year":"2019","unstructured":"Gui\u00e8ze R, et al. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell. 2019;36(4):369\u2013e38413.","journal-title":"Cancer Cell"},{"issue":"5","key":"2117_CR45","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","volume":"10","author":"M Konopleva","year":"2006","unstructured":"Konopleva M, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10(5):375\u201388.","journal-title":"Cancer Cell"},{"issue":"16","key":"2117_CR46","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1182\/blood-2009-07-233304","volume":"115","author":"D Yecies","year":"2010","unstructured":"Yecies D, et al. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood. 2010;115(16):3304\u201313.","journal-title":"Blood"},{"key":"2117_CR47","unstructured":"Tan L, et al. FoxO1 Deficiency in M-MDSCs Exacerbates B Cell Dysfunction in Systemic Lupus Erythematosus. Arthritis Rheumatol; 2024."},{"key":"2117_CR48","doi-asserted-by":"crossref","unstructured":"Chan FF et al. N6-Methyladenosine (m6A) modification activates serine synthesis pathway to mediate therapeutic resistance in liver cancer. Mol Ther, 2024.","DOI":"10.1016\/j.ymthe.2024.10.025"},{"key":"2117_CR49","doi-asserted-by":"crossref","unstructured":"Zhang F et al. m(6)A\/YTHDF2-mediated mRNA decay targets TGF-\u03b2 signaling to suppress the quiescence acquisition of early postnatal mouse hippocampal NSCs. Cell Stem Cell, 2024.","DOI":"10.1016\/j.stem.2024.10.002"},{"issue":"4","key":"2117_CR50","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.62347\/NXDR1826","volume":"14","author":"W Cui","year":"2024","unstructured":"Cui W, et al. Roles of RNA m(5)C modification patterns in prognosis and tumor microenvironment infiltration of diffuse large B-cell lymphoma. Am J Cancer Res. 2024;14(4):1768\u201383.","journal-title":"Am J Cancer Res"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02117-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02117-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02117-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:38:54Z","timestamp":1781642334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02117-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,22]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2117"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02117-3","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,22]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This submission has been approved for publication by all authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}}],"article-number":"204"}}